RxDoctor Payments Data

Isaac Wiener, MD

Clinical Cardiac Electrophysiology · Los Angeles, CANPI 1427041078

Payments from drug & device makers

$62,725in general payments, 2019–2025

Across 74 payments — averaging $847.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$52K
  • Boston Scientific$10K
  • Abbott$950
  • Amarin Pharma, Inc.$142
  • Amgen$100
  • E.r. Squibb & Sons, L.L.C.$84
  • plus $195 from 6 others

What the payments were for

  • Food & beverage$60799%
  • Education$61%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$62,725 in reported general payments places this provider in the 60th percentile of 290 clinical cardiac electrophysiology providers in California.

See all clinical cardiac electrophysiology providers in California

Medicare billing

Part B allowed, 2024
$730,996
Medicare patients
807
Services billed
6,843

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban418$409,010
XareltoRivaroxaban67$66,801
MultaqDronedarone Hcl41$48,510
Praluent PenAlirocumab39$31,550
Repatha SureclickEvolocumab32$25,549
EntrestoSacubitril/Valsartan20$17,563
FarxigaDapagliflozin Propanediol15$11,259
Repatha SyringeEvolocumab15$10,476
VascepaIcosapent Ethyl15$8,423
Ezetimibe156$5,040
Icosapent Ethyl15$4,278
Rosuvastatin Calcium271$4,221
Diltiazem 24hr Er (Cd)Diltiazem Hcl94$3,507
Amiodarone Hcl51$3,266
Metoprolol Succinate138$1,922

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$25$409,010418 claims
Johnson & JohnsonXarelto$37$66,80167 claims
AstraZenecaFarxiga$19$11,25915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 290 clinical cardiac electrophysiology providers in California.

Other clinical cardiac electrophysiology in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →